Introduction:
Abzena invests US$5 million to expand its bioconjugate development and cGMP manufacturing site in Pennsylvania, USA.
Features:
The investment in expanding laboratory space, acquiring new equipment, and upgrading facilities enhances the existing bioconjugation capabilities of the site and augments its capacity to support comprehensive biopharmaceutical drug programmes.
As part of this expansion initiative, the investments in five cutting-edge Waters Arc Premier LC Systems and two ACQUITY Premier Chromatography Systems, are made aiming to ensure consistent and reliable product analysis from the initial development phases through cGMP release and stability testing.
The recent investment significantly boosts the Bristol facility by expanding and optimising its quality control (QC) and analytical laboratory configurations and technologies, leading to enhanced efficiencies.
Furthermore, the site has undergone comprehensive renovations in its non-laboratory areas, which involve the installation of new flooring, implementation of modern lighting systems, and revitalisation of communal spaces.
These efforts aim to enhance efficiencies and enhance the working environment for colleagues.
Specifications:
Name Abzena
Type Expansion
Budget US$5 million
